{"product_id":"cjc-1295-no-dac-ipamorelin-10mg","title":"CJC-1295 no DAC + Ipamorelin 10mg","description":"\u003cp\u003e\u003cstrong\u003eBuy high-purity CJC-1295 + Ipamorelin blend (10mg) in Australia. Third-party lab tested at \u0026gt;99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch2\u003eAbout CJC-1295 + Ipamorelin\u003c\/h2\u003e\n\u003cp\u003eCJC-1295 (no-DAC) and ipamorelin are two complementary growth-hormone-axis research peptides that are frequently co-studied as a blend. CJC-1295 (no-DAC), also known as Mod GRF 1-29, is a tetrasubstituted analogue of growth-hormone-releasing hormone (GHRH 1-29) that binds the GHRH receptor on somatotrophs of the anterior pituitary. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist — a pentapeptide growth hormone secretagogue. In published endocrinology research, the two peptides act on distinct but complementary pathways: GHRH-receptor activation increases the amplitude of natural GH pulses, while a selective GH secretagogue can synergistically increase pulse frequency.\u003c\/p\u003e\n\u003cp\u003eOptic Labs supplies CJC-1295 (no-DAC) and ipamorelin as a co-lyophilised research blend at 10mg total fill (5mg CJC-1295 + 5mg ipamorelin), third-party HPLC tested to \u0026gt;99% purity for each component. The product is distributed Australian-domestic from Sydney, NSW, for in vitro and laboratory research applications. The blend is supplied strictly for laboratory research, development or analytical use and is not intended for human consumption.\u003c\/p\u003e\n\n\u003ch2\u003eProduct specifications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompound:\u003c\/strong\u003e CJC-1295 (no-DAC, also known as Mod GRF 1-29) co-lyophilised with ipamorelin\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCAS numbers:\u003c\/strong\u003e CJC-1295 (no-DAC): 863288-34-0; ipamorelin: 170851-70-4\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular formula:\u003c\/strong\u003e CJC-1295 (no-DAC): C\u003csub\u003e152\u003c\/sub\u003eH\u003csub\u003e252\u003c\/sub\u003eN\u003csub\u003e44\u003c\/sub\u003eO\u003csub\u003e42\u003c\/sub\u003e; ipamorelin: C\u003csub\u003e38\u003c\/sub\u003eH\u003csub\u003e49\u003c\/sub\u003eN\u003csub\u003e9\u003c\/sub\u003eO\u003csub\u003e5\u003c\/sub\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e CJC-1295 (no-DAC): ~3367.9 g\/mol; ipamorelin: ~711.85 g\/mol\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSequence (CJC-1295 no-DAC):\u003c\/strong\u003e Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSequence (ipamorelin):\u003c\/strong\u003e Aib-His-D-2-Nal-D-Phe-Lys-NH\u003csub\u003e2\u003c\/sub\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder (combined fill)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% by HPLC for each component\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAvailable size:\u003c\/strong\u003e 10mg total (5mg CJC-1295 no-DAC + 5mg ipamorelin)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e 2–8°C, protect from light. Reconstituted: 2–8°C, used within 30 days.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrigin:\u003c\/strong\u003e Manufactured to research-grade specifications, third-party HPLC verified\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShipping:\u003c\/strong\u003e Australia-wide domestic dispatch from Sydney, NSW\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eResearch background\u003c\/h2\u003e\n\u003cp\u003eCJC-1295 (no-DAC) was developed by ConjuChem in the early 2000s as a stabilised GHRH analogue, with four amino-acid substitutions to the native GHRH 1-29 sequence that resist proteolytic degradation. The \"no-DAC\" variant lacks the drug affinity complex linker present on the longer-acting CJC-1295 with DAC, giving it a shorter functional duration that more closely matches natural GH pulse kinetics. Ipamorelin was developed by Novo Nordisk as a selective GHS-R1a agonist designed to stimulate GH release without significant cortisol or prolactin responses, in contrast to earlier ghrelin-receptor agonists such as GHRP-6 and GHRP-2.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDual-pathway GH stimulation:\u003c\/strong\u003e in published endocrinology research, GHRH-receptor agonism (CJC-1295) and ghrelin-receptor agonism (ipamorelin) act through complementary intracellular pathways, with the combination producing larger GH pulses than either alone in animal model and isolated pituitary cell research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePulsatile release pattern:\u003c\/strong\u003e in animal models, the no-DAC variant of CJC-1295 has been studied for its capacity to amplify GH pulses while preserving the natural pulsatile pattern, distinguishing it from continuous-exposure GH-axis research compounds.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSelectivity profile (ipamorelin):\u003c\/strong\u003e in receptor-binding and rodent endocrine studies, ipamorelin showed minimal stimulation of cortisol, prolactin or aldosterone, distinguishing it from non-selective GHS such as GHRP-6.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIGF-1 axis:\u003c\/strong\u003e in animal model research, GH-axis stimulation by CJC-1295 + ipamorelin has been associated with downstream increases in IGF-1, the principal mediator of many of GH's tissue effects.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBody composition models:\u003c\/strong\u003e in rodent research, GH-axis stimulation has been studied in connection with adipose tissue lipolysis and lean mass parameters.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSleep architecture research:\u003c\/strong\u003e in published research, GH-axis activity is closely tied to slow-wave sleep, and GH-secretagogue research peptides have been studied in models of sleep architecture.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRecovery and tissue research:\u003c\/strong\u003e GH\/IGF-1 axis activity is studied in animal model research on connective tissue, bone metabolism and post-injury recovery.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a more detailed research summary, see our \u003ca href=\"\/blogs\/news\/cjc-1295-ipamorelin-growth-hormone-stack-guide\"\u003eCJC-1295 + ipamorelin GH stack research guide\u003c\/a\u003e and our \u003ca href=\"\/blogs\/news\/what-are-peptides-australia-explainer\"\u003ewhat are peptides explainer\u003c\/a\u003e. Researchers working with reconstitution should also reference our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003epeptide reconstitution guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eReconstitution and handling\u003c\/h2\u003e\n\u003cp\u003eThe combined 10mg vial reconstitutes readily in \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e. A common laboratory approach is reconstitution in 2ml to yield a 5mg\/ml total working stock (corresponding to 2.5mg\/ml CJC-1295 + 2.5mg\/ml ipamorelin), or in 5ml for a 2mg\/ml total stock (1mg\/ml of each component). The bacteriostatic water should be drawn into a sterile syringe and injected slowly down the inside wall of the lyophilised vial, with the peptide cake allowed to dissolve passively rather than through agitation. Reconstituted blend should be aliquoted, refrigerated at 2–8°C and protected from light, with research stocks typically used within 30 days. For dilution maths across alternative volumes, see our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003ereconstitution calculator guide\u003c\/a\u003e. For long-term storage protocols, see our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eCommonly stacked research peptides\u003c\/h2\u003e\n\u003cp\u003eIn published research and laboratory protocols, CJC-1295 + ipamorelin is often co-investigated alongside other recovery, body-composition and longevity research peptides:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/bpc-157\"\u003eBPC-157\u003c\/a\u003e — pentadecapeptide co-investigated with GH-axis research peptides in tissue-repair and recovery models.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/tb-500\"\u003eTB-500\u003c\/a\u003e — Thymosin β4 fragment commonly examined alongside GH-axis stimulation in injury and recovery research.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/tesamorelin-10mg\"\u003eTesamorelin\u003c\/a\u003e — alternative GHRH analogue studied in body composition and visceral adipose tissue research.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/sermorelin-10mg\"\u003eSermorelin\u003c\/a\u003e — shorter GHRH 1-29 analogue investigated in endocrine research as an alternative GHRH-axis compound.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/nad-1000mg\"\u003eNAD+\u003c\/a\u003e — co-investigated alongside GH-axis research compounds in longevity and mitochondrial study designs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor broader context on combined research designs, see our \u003ca href=\"\/blogs\/news\/peptide-research-stacks-australia-combinations\"\u003epeptide research stacks overview\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently asked questions\u003c\/h2\u003e\n\n\u003ch3\u003eIs CJC-1295 + ipamorelin legal in Australia?\u003c\/h3\u003e\n\u003cp\u003eCJC-1295 and ipamorelin are not registered therapeutic goods in Australia, and growth-hormone-releasing peptides are subject to specific regulatory oversight by the Therapeutic Goods Administration. Optic Labs supplies the CJC-1295 + ipamorelin blend strictly for laboratory, research and analytical use only, not as a therapeutic good. For a full overview of how the TGA treats research peptides in Australia, see our \u003ca href=\"\/blogs\/news\/are-peptides-legal-australia-tga-compliance-2025\"\u003epeptide legality and TGA compliance guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is CJC-1295 + ipamorelin?\u003c\/h3\u003e\n\u003cp\u003eCJC-1295 (no-DAC) is a stabilised GHRH 1-29 analogue that activates the GHRH receptor; ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist. The two are co-supplied as a research blend because they activate complementary pathways of GH release in published endocrinology research. For a research-level summary, see our \u003ca href=\"\/blogs\/news\/cjc-1295-ipamorelin-growth-hormone-stack-guide\"\u003eCJC-1295 + ipamorelin research guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is the difference between CJC-1295 with DAC and CJC-1295 without DAC?\u003c\/h3\u003e\n\u003cp\u003eThe \"DAC\" (drug affinity complex) is a maleimide linker that binds CJC-1295 to serum albumin, extending its functional half-life from hours to several days. CJC-1295 with DAC produces sustained GHRH-receptor exposure, while CJC-1295 no-DAC (Mod GRF 1-29) produces shorter pulses that more closely resemble the natural pulsatile pattern of GH release. Optic Labs supplies the no-DAC variant in this blend, which is the variant most commonly co-investigated with ipamorelin in published research.\u003c\/p\u003e\n\n\u003ch3\u003eWhy are CJC-1295 and ipamorelin commonly studied together?\u003c\/h3\u003e\n\u003cp\u003eThe two peptides act through distinct receptors — the GHRH receptor and the ghrelin receptor — that converge on the same somatotroph cell population in the anterior pituitary. In published endocrinology research, simultaneous activation of both pathways produces larger GH pulses than either compound alone, providing a useful tool for studying maximal physiological GH release.\u003c\/p\u003e\n\n\u003ch3\u003eHow is the blend supplied?\u003c\/h3\u003e\n\u003cp\u003eOptic Labs supplies CJC-1295 (no-DAC) and ipamorelin as a co-lyophilised powder in 10mg glass research vials (5mg of each component). Each vial is sealed with a tamper-evident closure. Certificates of analysis showing HPLC purity testing for each component are available on request.\u003c\/p\u003e\n\n\u003ch3\u003eHow much bacteriostatic water do I mix with a 10mg blend vial?\u003c\/h3\u003e\n\u003cp\u003eFor the 10mg combined vial, 2ml of \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e yields a 5mg\/ml total working stock (2.5mg of each peptide per ml); 5ml yields a 2mg\/ml total stock (1mg of each per ml); 1ml yields a 10mg\/ml stock (5mg of each per ml). Choose a volume based on the concentrations required by the research protocol. For a worked example, see our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003ereconstitution calculator guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eHow should the reconstituted blend be stored?\u003c\/h3\u003e\n\u003cp\u003eReconstituted CJC-1295 + ipamorelin should be stored at 2–8°C, protected from light, and used within approximately 30 days. For longer-term storage, aliquoting and freezing at −20°C or below is preferred to limit freeze-thaw degradation. Full handling protocols are covered in our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage research guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhere does Optic Labs ship to?\u003c\/h3\u003e\n\u003cp\u003eOptic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.\u003c\/p\u003e\n\n\u003ch2\u003eLegal disclaimer\u003c\/h2\u003e\n\u003cp\u003eAll products on this site are supplied for \u003cstrong\u003elaboratory research, development or analytical use only\u003c\/strong\u003e. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the \u003cstrong\u003eTherapeutic Goods Administration (TGA)\u003c\/strong\u003e or the \u003cstrong\u003eAPVMA\u003c\/strong\u003e and are not intended to diagnose, treat, cure or prevent any disease. Optic Labs is not a \u003cstrong\u003ecompounding pharmacy\u003c\/strong\u003e or manufacturing facility as defined under the \u003cem\u003eTherapeutic Goods Act 1989\u003c\/em\u003e, and is not a registered provider of scheduled medicines or therapeutic goods.\u003c\/p\u003e","brand":"Optic Labs","offers":[{"title":"Default Title","offer_id":53360884940984,"sku":null,"price":94.99,"currency_code":"AUD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0952\/4196\/1656\/files\/cjcnodacipa10_b8fecb4a-8ce2-4e95-a59d-de0a9c3ec796.png?v=1776427781","url":"https:\/\/opticlabsau.com\/products\/cjc-1295-no-dac-ipamorelin-10mg","provider":"Optic Labs","version":"1.0","type":"link"}